Literature DB >> 26768612

Expression of Pim-3 in colorectal cancer and its relationship with prognosis.

Zhongguo Zhou1, Rongxin Zhang1, Ruojing Wang2, Yaojun Zhang1, Li Xu1, Jinbin Chen1, Jie Zhang1, Zhongxi Huang1, Minshan Chen3, Zhizhong Pan4.   

Abstract

There is increasing evidence suggesting that the establishment of Pim-3 is involved in tumorigenesis. This study aimed to investigate the expression and clinicopathological significance of Pim-3 in colorectal cancer (CRC). Clinical pathology data were collected from 410 CRC patients who received radical resection and were pathologically confirmed at the Sun Yat-Sen University Cancer Center between October 2002 and December 2008. We compared the expression Pim-3 in the primary focus and liver metastasis and investigated the correlations with other clinical-pathological factors. Multivariate analysis showed that perioperative blood transfusion, local invasion, lymph node and liver metastasis, and Pim-3 expression were independent prognostic factors. The expression of Pim-3 in CRC was higher than that in normal tissues. Patients with positive expression had significant decreases in 5-year survival. Pim-3 expression showed a positive correlation with tumor cell differentiation, local infiltration, and lymph node and liver metastasis. In conclusion, Pim-3 might serve as a novel target and prognosis factor for colorectal cancer.

Entities:  

Keywords:  Colorectal cancer; Metastasis; Pim-3; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 26768612     DOI: 10.1007/s13277-016-4806-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

Review 1.  Roles of Pim-3, a novel survival kinase, in tumorigenesis.

Authors:  Naofumi Mukaida; Ying-Ying Wang; Ying-Yi Li
Journal:  Cancer Sci       Date:  2011-05-23       Impact factor: 6.716

2.  Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.

Authors:  Hao Zhuang; Man-Yin Zhao; Kai-Wen Hei; Bai-Cai Yang; Li Sun; Xue Du; Yong-Mei Li
Journal:  Asian Pac J Cancer Prev       Date:  2015

3.  Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach.

Authors:  Lei Lou; Yuan Wang; Jinfeng Cui; Xia Yan; Liying Xue; Yuehong Li
Journal:  Tumour Biol       Date:  2014-02-02

4.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

5.  Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells.

Authors:  Fabiola Cervantes-Gomez; Bethany Lavergne; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2015-09-28

6.  Report of incidence and mortality in China cancer registries, 2009.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Guanglin Li; Lingyou Wu; Jie He
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

7.  MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells.

Authors:  Guoqiang Zhang; Zengyan Liu; Guanghe Cui; Xiaohong Wang; Zhenlin Yang
Journal:  Tumour Biol       Date:  2014-08-08

8.  Binding site identification and role of permanent water molecule of PIM-3 kinase: A molecular dynamics study.

Authors:  Zaheer Ul-Haq; Sana Gul; Saman Usmani; Abdul Wadood; Waqasuddin Khan
Journal:  J Mol Graph Model       Date:  2015-09-15       Impact factor: 2.518

Review 9.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Authors:  Alberto Bardelli; Salvatore Siena
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.

Authors:  Chen Liang; Xian-Jun Yu; Xiao-Zhong Guo; Meng-Hong Sun; Zhen Wang; Yao Song; Quan-Xing Ni; Hong-Yu Li; Naofumi Mukaida; Ying-Yi Li
Journal:  Oncotarget       Date:  2015-06-10
View more
  5 in total

1.  Long non-coding RNA (FALEC) promotes malignant behaviors of gastric cancer cells by regulating miR-203b/PIM3 axis.

Authors:  Wenjing Dong; Mancheng Gong; Jianjun Xiao; Huifen Li; Muyou Tian; Senming Wang
Journal:  Ann Transl Med       Date:  2022-05

2.  Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer.

Authors:  Kaili Liu; Hui Gao; Qiaoyun Wang; Longyuan Wang; Bin Zhang; Zhiwu Han; Xuehong Chen; Mei Han; Mingquan Gao
Journal:  Cancer Sci       Date:  2018-04-17       Impact factor: 6.716

3.  Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.

Authors:  Holly Koblish; Yun-Long Li; Niu Shin; Leslie Hall; Qian Wang; Kathy Wang; Maryanne Covington; Cindy Marando; Kevin Bowman; Jason Boer; Krista Burke; Richard Wynn; Alex Margulis; Gary W Reuther; Que T Lambert; Valerie Dostalik Roman; Ke Zhang; Hao Feng; Chu-Biao Xue; Sharon Diamond; Greg Hollis; Swamy Yeleswaram; Wenqing Yao; Reid Huber; Kris Vaddi; Peggy Scherle
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

4.  ceRNA Networks: The Backbone Role in Neoadjuvant Chemoradiotherapy Resistance/Sensitivity of Locally Advanced Rectal Cancer.

Authors:  Lin He; Hao Chang; Yuhong Qi; Bing Zhang; Qiuju Shao
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

5.  Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.

Authors:  Rong-Xin Zhang; Zhong-Guo Zhou; Shi-Xun Lu; Zhen-Hai Lu; De-Sen Wan; Zhi-Zhong Pan; Xiao-Jun Wu; Gong Chen
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.